Biological Therapies in IgE-Mediated Food Allergy: Narrative review
DOI:
https://doi.org/10.12775/JEHS.2026.95.73652Keywords
food allergy, omalizumab, IgE, biologics, oral immunotherapy, anaphylaxis, mast cell, Th2Abstract
IgE-mediated food allergy is a chronic immune-mediated condition of growing global concern, carrying the risk of severe and potentially fatal allergic reactions. For decades, clinical management rested entirely on allergen avoidance and emergency epinephrine, with no approved disease-modifying therapy available. The recent regulatory approval of omalizumab, a monoclonal anti-IgE antibody, as the first biologic licensed specifically for the reduction of multi-food allergic reactions marks a paradigm shift in this field. This literature review examines the immunological rationale for biologic intervention in IgE-mediated food allergy, synthesises the pivotal evidence from the OUtMATCH clinical trial programme, and surveys the emerging pipeline of agents currently under investigation including dupilumab and anti-alarmin therapies. The comparative evidence between biologics and oral immunotherapy is appraised, and the most pressing evidence gaps and future research priorities are identified.
References
Anagnostou, A. (2024). A decade of progress in prevention and management of food allergy and anaphylaxis. Journal of Food Allergy, 6(1), 1–2. https://pmc.ncbi.nlm.nih.gov/articles/PMC11382764/
Beck, L.A., et al. (2004). Omalizumab-induced reductions in mast cell FcεRI expression and function. Journal of Allergy and Clinical Immunology, 114(3), 527–530. https://pubmed.ncbi.nlm.nih.gov/15356552/
Baloh, C.H., Huffaker, M.F., & Laidlaw, T. (2022). Biomarkers and mechanisms of tolerance induction in food allergic patients drive new therapeutic approaches. Frontiers in Immunology, 13, 972103. https://pubmed.ncbi.nlm.nih.gov/36263023/
Berin, M.C. (2023). Targeting type 2 immunity and the future of food allergy treatment. Journal of Experimental Medicine, 220(4), e20221104 https://pubmed.ncbi.nlm.nih.gov/36880703/
Bingemann, T.A., et al. (2024). Psychosocial impact of food allergy on children and adults and practical interventions. Current Allergy and Asthma Reports, 24(3), 107–119. https://pmc.ncbi.nlm.nih.gov/articles/PMC11250200/
Chinthrajah, R.S., et al. (2025). Dupilumab as an adjunct to oral immunotherapy in paediatric patients with peanut allergy. Allergy, 80(3), 827–842. https://pubmed.ncbi.nlm.nih.gov/39673367/
Corren, J., et al. (2023). Effects of combination tezepelumab and allergen immunotherapy on nasal responses to cat allergen. Journal of Allergy and Clinical Immunology, 151(6), 1574–1582. https://pubmed.ncbi.nlm.nih.gov/36764361/
Cushman, G.K., et al. (2023). Psychosocial functioning in pediatric food allergies: a scoping review. Journal of Allergy and Clinical Immunology, 151(1), 29–36. https://pubmed.ncbi.nlm.nih.gov/36195171/
Drakouli, A.E., et al. (2023). Food allergies and quality of life among school-aged children and adolescents: a systematic review. Children, 10(3), 433. https://pmc.ncbi.nlm.nih.gov/articles/PMC10047601/
Dreskin, S.C., et al. (2025). Scientific developments in understanding food allergy prevention, diagnosis, and treatment. Frontiers in Immunology, 16, 1572283. https://pubmed.ncbi.nlm.nih.gov/40370445/
Eckman, J.A., et al. (2010). Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. Journal of Allergy and Clinical Immunology, 125(4), 889–895.https://pmc.ncbi.nlm.nih.gov/articles/PMC2850969/
Fitzhugh, D.J. (2025). Prediction of food allergy reaction severity: biomarkers and host factors. Frontiers in Allergy, 6, 1578601. https://www.frontiersin.org/journals/allergy/articles/10.3389/falgy.2025.1578601/full
Johansson, M.W., & Gunderson, K.A. (2018). Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Frontiers in Immunology, 9, 549. https://pmc.ncbi.nlm.nih.gov/articles/PMC5915348/
Lodge, C.J., et al. (2023). Efficacy and safety of oral immunotherapy for peanut, cow's milk, and hen's egg allergy: a systematic review of randomized controlled trials. Clinical and Translational Allergy, 13(7), e12268 https://pubmed.ncbi.nlm.nih.gov/37488726/
MacGlashan, D.W., et al. (2007). Omalizumab reverses the phenotypic and functional effects of IgE-enhanced FcεRI on human skin mast cells. Journal of Allergy and Clinical Immunology, 120(1), 64–72.https://pmc.ncbi.nlm.nih.gov/articles/PMC2396781/
MacGlashan, D.W. (2015). Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation. Journal of Allergy and Clinical Immunology, 135(3), 748–756.https://pmc.ncbi.nlm.nih.gov/articles/PMC4302343/
Nilsson, C., et al. (2023). Long-term safety and immunologic outcomes of daily oral immunotherapy for peanut allergy. Journal of Allergy and Clinical Immunology: Global, 2(3), 100120. https://pmc.ncbi.nlm.nih.gov/articles/PMC10509957/
Nurmatov, U., et al. (2025). Biologics in IgE-mediated food allergy: a systematic review and meta-analysis of interventional studies. World Allergy Organization Journal, 18(7), 101069.https://pmc.ncbi.nlm.nih.gov/articles/PMC12158532/
Parisi, C.A.S., et al. (2024). Dupilumab as a therapeutic option in polysensitised atopic dermatitis patients suffering from food allergy. Nutrients, 16(16), 2797. https://pmc.ncbi.nlm.nih.gov/articles/PMC11356865/
Prussin, C., et al. (2003). Omalizumab treatment downregulates dendritic cell FcεRI expression. Journal of Allergy and Clinical Immunology, 112(6), 1147–1154. https://pubmed.ncbi.nlm.nih.gov/14657874/
Rabin, R.L., et al. (2025). Biomarker-driven drug development for allergic diseases and asthma: an FDA public workshop. Journal of Allergy and Clinical Immunology, 155(6), 1753–1766. https://pubmed.ncbi.nlm.nih.gov/40154576/
Ramsey, N., & Berin, M.C. (2021). Pathogenesis of IgE-mediated food allergy and implications for future immunotherapeutics. Pediatric Allergy and Immunology, 32(7), 1416–1425.https://pmc.ncbi.nlm.nih.gov/articles/PMC9096874/
Shaker, M.S. (2024). Anaphylaxis: Definition and criteria. Journal of Food Allergy, 6(1), 26–31.https://pmc.ncbi.nlm.nih.gov/articles/PMC11382771/
Shreffler, W.G. (2020). Pathophysiology of immunoglobulin E–mediated food allergy. Journal of Food Allergy, 2(1), 7–10. https://pmc.ncbi.nlm.nih.gov/articles/PMC11250434/
Sindher, S.B., et al. (2023). Treatment of food allergy: oral immunotherapy, biologics and beyond. Annals of Allergy, Asthma and Immunology, 131(1), 29–36. https://pmc.ncbi.nlm.nih.gov/articles/PMC10330596/
Sindher, S.B., et al. (2024). The role of biologics in the treatment of food allergy. Journal of Allergy and Clinical Immunology: In Practice, 12(3), 562–568. https://pmc.ncbi.nlm.nih.gov/articles/PMC11104487/
Sindher, S.B., et al. (2025). Efficacy and safety of dupilumab in children with peanut allergy: a phase II study. Allergy, 80(1), 227–237. https://pubmed.ncbi.nlm.nih.gov/39673452/
Spekhorst, L.S., et al. (2024). Dupilumab induces a significant decrease of food-specific IgE levels in paediatric atopic dermatitis patients. Clinical and Translational Allergy, 14(7), e12377.https://pmc.ncbi.nlm.nih.gov/articles/PMC11254451/
Vickery, B.P., et al. (2022). Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective: the IMPACT trial. Lancet, 399(10322), 359–371. https://pmc.ncbi.nlm.nih.gov/articles/PMC9119642/
Warren, C.M., Jiang, J., & Gupta, R.S. (2020). Epidemiology and burden of food allergy. Current Allergy and Asthma Reports, 20(2), 6. https://pmc.ncbi.nlm.nih.gov/articles/PMC7883751/
Warren, C.M., et al. (2021). The psychosocial burden of food allergy among adults: a US population-based study. Journal of Allergy and Clinical Immunology: In Practice, 9(6), 2452–2460.https://pmc.ncbi.nlm.nih.gov/articles/PMC9190169/
Warren, C.M., et al. (2023). The epidemiology of multi-food allergy in the United States. Annals of Allergy, Asthma and Immunology, 130(5), 637–648. https://pmc.ncbi.nlm.nih.gov/articles/PMC10217773/
Whyte, A.F., et al. (2022). Emergency treatment of anaphylaxis: concise clinical guidance. Clinical Medicine, 22(4), 332–339. https://pmc.ncbi.nlm.nih.gov/articles/PMC9345203/
Wood, R.A., et al. (2024). Omalizumab for the treatment of multiple food allergies. New England Journal of Medicine, 390(10), 889–899. https://pubmed.ncbi.nlm.nih.gov/38446676/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Marcelina Rybińska, Hanna Rzepka, Paweł Stępowski, Mateusz Tajster
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 59
Number of citations: 0
